Latest Hotspot

Kodiak's innovative therapy, tarcocimab tedromer, reaches primary endpoint in Phase 3 trial for the treatment of diabetic retinopathy

10 November 2023
3 min read

Recently, Kodiak Sciences announced that its Phase III GLOW study of tarcocimab tedromer, a 5 mg dose of an antibody-biocopolymer conjugate (ABC) therapy for the treatment of moderate to severe non-proliferative diabetic retinopathy (NPDR) patients, achieved its primary endpoint at one year. Following treatment every six months, improvements and stability in the vision and retinal anatomy of NPDR patients were observed.

图形用户界面, 文本, 应用程序, 电子邮件

描述已自动生成

Tarcocimab tedromer (KSI-301) is a long-acting anti-vascular endothelial growth factor (VEGF) therapy developed by Kodiak based on its proprietary ABC platform. By coupling VEGF antibodies to a highly hydrophobic phosphocholine copolymer, it specifically binds to VEGF to downregulate VEGF levels and significantly prolongs the half-life of the VEGF antibody in the vitreous, thereby achieving longer effectiveness and reducing the frequency of administration. In vitro test results have shown that KSI-301 compared to the Maximal Inhibition of ranibizumab and abicipar had improved inhibition of HRMVEC cell proliferation.

Analyses indicated the GLOW study achieved its primary endpoint - the ratio of patients whose Diabetic Retinopathy Severity Score (DRSS) improved by at least two levels. In patients treated with tarcocimab, 41.1% of evaluable patients improved by at least 2 levels, compared to just 1.4% in the sham treatment control group (P<0.0001), a 29-fold increase in response rate. Vision and retinal anatomy improved and remained stable even after extending the dosing interval. The GLOW study also met all key secondary endpoints, including significantly greater reductions in the proportion of patients with vision-threatening complications (such as diabetic macular edema and proliferative diabetic retinopathy) compared to the control group. This equated to an 89% risk reduction, or 21.0% compared to 2.3% (P<0.0001). The risk of developing diabetic macular edema was reduced by 95% compared to the control group, with incidence rates of 13.7% in the control group and 0.7% in the tarcocimab group. Similar incidence rates of serious ocular adverse events and intra-ocular inflammation were observed in both groups.

图形用户界面, 表格

描述已自动生成

According to the information disclosed by the Synapse Database, as of November 9, 2023, there are 297 drugs under research targeted at VEGF, applied for 183 indications, by 377 institutions, involved in 5130 clinical trials, and filed for as many as 68663 patents. On July 24, 2023, Kodiak Sciences released the latest data from three Phase III studies of tarcocimab tedromer for the treatment of AMD and DME, none of which achieved the primary endpoint, resulting in a significant fall in share price. The recent achievement of the one-year primary endpoint in the phase III GLOW study of tarcocimab tedromer for the treatment of moderate to severe NPDR patients could see a turnaround. The results are eagerly awaited.

图形用户界面, 文本, 应用程序

描述已自动生成

T-cell co-stimulation target: 4-1BB (CD137)
T-cell co-stimulation target: 4-1BB (CD137)
10 November 2023
4-1BB (also known as CD137 or TNFRSF9) was first discovered in 1989 and is a critical co-stimulation receptor on T cells and other immune cells.
Read →
Abbisko Therapeutics' FGFR4 inhibitor, ABSK012, has received FDA clinical trial approval for the treatment of advanced solid tumors
Latest Hotspot
3 min read
Abbisko Therapeutics' FGFR4 inhibitor, ABSK012, has received FDA clinical trial approval for the treatment of advanced solid tumors
10 November 2023
Abbisko Therapeutics recently reported that its self-developed small molecule FGFR4 inhibitor ABSK012, aimed at drug-resistant mutations, has received FDA approval to begin phase I human trials with advanced solid tumor patients.
Read →
Latest Research Progress on TLR Adjuvants
Latest Research Progress on TLR Adjuvants
10 November 2023
The TLR agonists used in vaccine formulations come in various forms, ranging from lipopeptides to single-stranded DNA and RNA.
Read →
The phase 2 clinical trial results of MoonLake's innovative nanobody treatment, Sonelokimab, have shown positive outcomes, effectively alleviating psoriasis
Latest Hotspot
3 min read
The phase 2 clinical trial results of MoonLake's innovative nanobody treatment, Sonelokimab, have shown positive outcomes, effectively alleviating psoriasis
10 November 2023
MoonLake Immunotherapeutics recently announced positive results from the global Phase 2 clinical trial, ARGO, assessing the efficacy and safety of its nanobody, sonelokimab, in patients with active psoriatic arthritis (PsA).
Read →
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.